Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor

Clinical trial NCT00582933 · COMPLETED

Trial details

NCT number: NCT00582933
Sponsor: Memorial Sloan Kettering Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Leukemia Myelodysplastic Syndrome Non-Hodgkin's Lymphoma Allogeneic Marrow Transplant

Start date: 2001-05-01
Primary completion: 2008-04-01
Enrollment: 96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.